Sanchari Sinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sanchari Sinha has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
A Abdul-Hai
Kaplan Medical Center, Rehovot, Israel
1 shared publicationA Onn
Institute of Pulmonary Oncology, Chaim Sheba Medical Center Ramat Gan, Israel
1 shared publication- Arkadeb Dutta
Department of Biomedical Science and Technology, Ramakrishna Mission Vivekananda Educational and Research Institute (RKMVERI), Kolkata, IND
1 shared publication - Deobrat Dixit
Department of Medicine, Division of Regenerative Medicine, University of California, San Diego, La Jolla, California
1 shared publication - Ellora Sen
National Brain Research Centre, Manesar, India
1 shared publication G Mills
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication
Latest Publications
- 27 April 2015
- Published by Springer Nature in Oncogene
- Vol. 35 (4) , 438-447
An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors
Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy. Although they might improve safety and delay onset of chemoresistance, no anti-ligand antibodies have been clinically approved. To identify suitable ligands, we surveyed fluids from ovarian and lung cancer patients and found that amphiregulin (AREG) is the most abundant and generalized ligand secreted by advanced tumors. AREG is a low affinity EGFR ligand, which is upregulated following treatment with chemotherapeutic drugs. Because AREG depletion retarded growth of xenografted ovarian tumors in mice, we generated a neutralizing monoclonal anti-AREG antibody. The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy efficacy. Taken together, these results raise the possibility that AREG and other low- or high-affinity binders of EGFR might serve as potential targets for cancer therapy.
- 27 April 2015
- Published by Springer Nature in Oncogene
- Vol. 35 (4) , 438-447
An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors
Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy. Although they might improve safety and delay onset of chemoresistance, no anti-ligand antibodies have been clinically approved. To identify suitable ligands, we surveyed fluids from ovarian and lung cancer patients and found that amphiregulin (AREG) is the most abundant and generalized ligand secreted by advanced tumors. AREG is a low affinity EGFR ligand, which is upregulated following treatment with chemotherapeutic drugs. Because AREG depletion retarded growth of xenografted ovarian tumors in mice, we generated a neutralizing monoclonal anti-AREG antibody. The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy efficacy. Taken together, these results raise the possibility that AREG and other low- or high-affinity binders of EGFR might serve as potential targets for cancer therapy.
- 1 November 2011
- Published by Elsevier in Cellular Signalling
- Vol. 23 (11) , 1869-1875
IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory responses in glioma
- 1 November 2011
- Published by Elsevier in Cellular Signalling
- Vol. 23 (11) , 1869-1875
IGF-1 induced HIF-1α-TLR9 cross talk regulates inflammatory responses in glioma
- 1 April 2010
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 171 (2) , 115-121
Protein nitration, lipid peroxidation and DNA damage at high altitude in acclimatized lowlanders and native highlanders: Relation with oxygen consumption
- 1 April 2010
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 171 (2) , 115-121
Protein nitration, lipid peroxidation and DNA damage at high altitude in acclimatized lowlanders and native highlanders: Relation with oxygen consumption
- 24 May 2009
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 106 (6) , 807-814
Antioxidant and redox status after maximal aerobic exercise at high altitude in acclimatized lowlanders and native highlanders
- 24 May 2009
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 106 (6) , 807-814
Antioxidant and redox status after maximal aerobic exercise at high altitude in acclimatized lowlanders and native highlanders